File uploads: We have fixed an issue which caused file uploads to fail. We apologise for the inconvenience it may have caused.

Published October 11, 2021 | Version v1
Book chapter Open

Autophagic processes in early- and late- onset Alzheimer's disease

  • 1. 1Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway
  • 2. 1Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway; The Norwegian Centre on Healthy Ageing (NO-Age), Oslo, Norway
  • 3. Memory Clinic, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic; International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic
  • 4. Department of Psychiatry, University of Oxford, Oxford, UK

Description

Autophagy plays a fundamental role in maintaining intracellular homeostasis and cell survival by degrading damaged and unnecessary subcellular components via the lysosome. Impaired autophagy is evident in otherwise ‘normal’ elderly individuals and patients with neurodegenerative diseases, such as Alzheimer’s disease (AD). As the most common type of dementia, AD is an age-associated disease with memory loss as the primary clinical feature, as well as extracellular Aβ plaques and intracellular Tau tangles as disease-defining pathological features. Recent studies in animal models of AD, AD patient-derived stem cells, and AD post-mortem brain tissues suggest that compromised mitophagy/autophagy, plays a causative role in AD progression. Supporting this hypothesis, pharmacological approaches to induce mitophagy/autophagy, e.g., the use of the small natural molecule NAD+, slow down AD progression in animal models. This chapter reviews the extant literature on autophagy in AD, covers recent progress on the molecular mechanisms of NAD+-dependent mitophagy/autophagy regulation and mechanisms underlying the anti-AD potential of NAD+. Further studies to define the NAD+-mitophagy/autophagy axis may shed light on novel therapeutics to treat AD, and potentially provide insights into other neurodegenerative diseases.    

Notes

E.F.F. is supported by Helse Sør-Øst (#2017056, #2020001, #2021021), the Research Council of Norway (#262175 and #277813), the National Natural Science Foundation of China (#81971327), an Akershus University Hospital Strategic grant (#269901), and a Rosa Sløyfe grant (#207819) from the Norwegian Cancer Society. E.F.F., M.V., K.C. have received funding from the EEA/ Norway Grants 2014-2021 and the Technology Agency of the Czech Republic - project number TO01000215

Files

Files (1.3 MB)

Name Size Download all
md5:8db7678a3852dc4911fb9e682bac6867
1.3 MB Download